ClinVar Miner

Submissions for variant NM_000329.3(RPE65):c.499G>T (p.Asp167Tyr)

gnomAD frequency: 0.00001  dbSNP: rs61752883
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 10
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ClinGen Leber Congenital Amaurosis/early Onset Retinal Dystrophy Variant Curation Expert Panel, ClinGen RCV004527316 SCV005038772 likely pathogenic RPE65-related recessive retinopathy 2024-04-22 reviewed by expert panel curation NM_000329.3(RPE65):c.499G>T (p.Asp167Tyr) is a missense variant predicted to replace aspartic acid with tyrosine at position 167. This variant is present in gnomAD v.2.1.1 at a GrpMax allele frequency of 0.000007020 with 3 alleles / 113490 total alleles in the European (non-Finnish) population, which is lower than the ClinGen LCA / eoRD VCEP PM2_Supporting threshold of <0.0002 (PM2_Supporting). This variant has been reported in at least 1 proband with early-onset severe retinal dystrophy who was homozygous for the variant (0.5 pts, PMID: 36547097). This variant has also been reported in at least 5 probands with early-onset severe retinal dystrophy who were compound heterozygous with the NM_000329.3(RPE65):c.16G>T (p.Glu6Ter), NM_000329.3(RPE65):c.292_311del (p.Ile98HisfsTer26), NM_000329.3(RPE65):c.938A>G (p.His313Arg), or NM_000329.3(RPE65):c.778_785del (p.Asn260GlnfsTer18) variants suspected in trans (2 pts, PMID: 11095629, PMID: 35129589, PMID: 25257057), as well as the NM_000329.3(RPE65):c.1580A>G (p.His527Arg) variant confirmed in trans (1 pt, PMID: 35904185), all of which were previously classified pathogenic or likely pathogenic by the ClinGen LCA / eoRD VCEP (3.5 total points, PM3_Strong). At least one proband harboring this variant exhibits a phenotype including diagnosis of Leber congenital amaurosis (0.5 pts, PMID: 25257057), undetectable ERG response from rods (0.5 pts) and reduced ERG responses from cones (1 pt, PMID: 18441371) and significant, documented improvement of retinal sensitivity by dark-adapted perimetry and microperimetry after treatment with RPE65 gene therapy (8 pts, PMID: 25938638), which together are highly specific for RPE65-related recessive retinopathy (total 10 pts, PP4_Moderate). The computational predictor REVEL gives a score of 0.93, which is above the ClinGen LCA / eoRD VCEP threshold of ≥0.773 and predicts a damaging effect on RPE65 function (PP3_Moderate). In summary, this variant meets the criteria to be classified as likely pathogenic for RPE65-related recessive retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA / eoRD VCEP: PM2_Supporting, PM3_Strong, PP3_Moderate, and PP4_Moderate. (VCEP specifications version 1.0.0; date of approval 09/21/2023).
GeneDx RCV000085203 SCV000491115 likely pathogenic not provided 2022-07-19 criteria provided, single submitter clinical testing Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 15288992, 18441371, 18774912, 17964524, 18055820, 25257057, 17724218, 11095629, 32032261)
Illumina Laboratory Services, Illumina RCV000778252 SCV000914424 likely pathogenic RPE65-related disorder 2018-12-11 criteria provided, single submitter clinical testing The RPE65 c.499G>T (p.Asp167Tyr) variant is a missense variant that has been reported in a compound heterozygous state in three individuals with either Leber congenital amaurosis or retinal dystrophy (Thompson et al. 2000; Simonelli et al. 2007; Bainbridge et al. 2008; Ripamonti et al. 2014). The p.Asp167Tyr variant was also identified in a heterozygous state in one additional case in whom a second variant was not identified (Henderson et al. 2007). The p.Asp167Tyr variant was absent from 50 control individuals but was reported at a frequency of 0.000026 in the European (non-Finnish) population of the Genome Aggregation Database. Functional studies of this variant have not been conducted, but it affects a conserved residue and in silico tools predict it to have a damaging effect. Based on the collective evidence, the p.Asp167Tyr variant is classified as likely pathogenic for RPE65-related disorders. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population.
Invitae RCV001245153 SCV001418423 pathogenic Leber congenital amaurosis 2; Retinitis pigmentosa 20 2024-01-22 criteria provided, single submitter clinical testing This sequence change replaces aspartic acid, which is acidic and polar, with tyrosine, which is neutral and polar, at codon 167 of the RPE65 protein (p.Asp167Tyr). This variant is present in population databases (rs61752883, gnomAD 0.003%). This missense change has been observed in individual(s) with retinal dystrophy (PMID: 11095629, 17724218, 18441371, 25257057, 28224992). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 98873). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on RPE65 protein function. For these reasons, this variant has been classified as Pathogenic.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV001831894 SCV002547975 pathogenic Leber congenital amaurosis 2022-05-26 criteria provided, single submitter clinical testing Variant summary: RPE65 c.499G>T (p.Asp167Tyr) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.2e-05 in 250964 control chromosomes. c.499G>T has been reported in the literature in multiple individuals affected with Leber Congenital Amaurosis, Inherited Retinal Degeneration, or other Retinitis pigmentosa. These data indicate that the variant is very likely to be associated with disease. Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation (Pathogenic n=1, likely pathogenic n=3, VUS n=1). Based on the evidence outlined above, the variant was classified as pathogenic.
Baylor Genetics RCV001250708 SCV004209308 pathogenic Leber congenital amaurosis 2 2021-11-16 criteria provided, single submitter clinical testing
Retina International RCV000085203 SCV000117340 not provided not provided no assertion provided not provided
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ RCV000678617 SCV000804705 uncertain significance Retinitis pigmentosa 20 2016-09-01 no assertion criteria provided clinical testing
Laboratory of Genetics in Ophthalmology, Institut Imagine RCV001250708 SCV001425586 likely pathogenic Leber congenital amaurosis 2 no assertion criteria provided research
Natera, Inc. RCV001831894 SCV002092769 likely pathogenic Leber congenital amaurosis 2021-05-04 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.